Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 5NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 142Myelodysplastic Syndromes 66Leukemia, Myelomonocytic, Chronic 33Neoplasms 17Leukemia 16Recurrence 14Hematologic Neoplasms 14Multiple Myeloma 11Lymphoma, Non-Hodgkin 9Lymphoma 7Carcinoma, Non-Small-Cell Lung 6Primary Myelofibrosis 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Lymphocytic, Chronic, B-Cell 5Neoplasm Metastasis 4Leukemia, Myeloid 4Hodgkin Disease 4Hematologic Diseases 4Prostatic Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Glioblastoma 3Breast Neoplasms 3Anemia, Refractory, with Excess of Blasts 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Renal Insufficiency 2

Interventions

10-propargyl-10-deazaaminopterin 6Brentuximab Vedotin 5romidepsin 3Vitamin B 12 3Rituximab 3Folic Acid 3Cyclophosphamide 3tenalisib 2cobomarsen 2belinostat 2Vincristine 2Prednisone 2Gemcitabine 2Doxorubicin 2zanubrutinib 1zanolimumab 1venetoclax 1tislelizumab 1quisinostat 1pembrolizumab 1mogamulizumab 1fostamatinib 1forodesine 1fludarabine 1enzastaurin 1enzalutamide 1duvelisib 1denileukin diftitox 1darinaparsin 1cc-486 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, T-Cell × Azacitidine × Clear all
NCT03703375 2024-07-08

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Celgene

Phase 3 Active not recruiting
93 enrolled 19 charts
Lymphoid

Lymphoma, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡